Request Expanded Access for Aviptadil (RLF-100) for your Patients
Thank you for your interest in the Expanded Access Program for Aviptadil (RLF-100). This program was authorized by the FDA as an Intermediate-size Expanded Access Program. Please note that this medication has not been approved by the FDA for any indication and is currently being studied in a clinical study of Intravenous Aviptadil for Critical COVID-19 with Respiratory Failure NCT04311697 (COVID-AIV).
Our Expanded Access Program is being managed by Clinigen.
Please note that NeuroRx and Clinigen are receiving a high volume of requests and we are working expeditiously to address these.
Due to the volume of requests, NeuroRx is unable to reply to voice mail messages on our system.